Armata Pharmaceuticals, Inc.
General ticker "ARMP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $172.6M (TTM average)
Armata Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 36.2%.
Estimated limits based on current volatility of 3.3%: low 7.68$, high 8.21$
Factors to consider:
- Total employees count: 66 (-12.0%) as of 2023
- Top business risk factors: Insufficient funding, Product liability, Controlled company status, Cybersecurity threats, Climate change and natural disasters
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.06$, 11.54$]
- 2026-12-31 to 2027-12-31 estimated range: [3.17$, 8.98$]
Financial Metrics affecting the ARMP estimates:
- Negative: with PPE of -4.3 at the end of fiscal year the price was high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of -0.24 > -0.60
- Negative: -0.16 < Industry inventory ratio change (median), % of 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term ARMP quotes
Long-term ARMP plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $4.53MM | $5.17MM | $4.90MM |
| Operating Expenses | $45.42MM | $47.61MM | $36.13MM |
| Operating Income | $-40.89MM | $-42.44MM | $-31.22MM |
| Non-Operating Income | $-28.16MM | $23.52MM | $-142.58MM |
| R&D Expense | $33.77MM | $34.43MM | $23.72MM |
| Income(Loss) | $-69.05MM | $-18.92MM | $-173.80MM |
| Net Income(Loss)* | $-69.05MM | $-18.92MM | $-173.80MM |
| Stockholders Equity | $-32.06MM | $-48.02MM | $-218.60MM |
| Assets | $98.36MM | $86.44MM | $76.88MM |
| Operating Cash Flow | $-47.42MM | $-37.55MM | $-25.76MM |
| Capital expenditure | $8.14MM | $1.88MM | $0.54MM |
| Investing Cash Flow | $-8.13MM | $-1.88MM | $-0.54MM |
| Financing Cash Flow | $53.99MM | $34.96MM | $25.61MM |
| Earnings Per Share** | $-1.91 | $-0.52 | $-4.80 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.